aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Delfi Diagnostics, founded with a mission to revolutionize cancer detection and prevention, focuses on developing high-performing, accessible blood tests for early cancer detection. Leveraging novel machine learning algorithms, Delfi's technology analyzes fragments of cell-free DNA to identify cancer from a single blood sample. Their flagship clinical trial, CASCADE-LUNG, aims to enroll approximately 15,000 participants, underscoring their commitment to scalable and accurate cancer screening solutions.
Notable figures associated with Delfi Diagnostics include Dr. Velculescu, an internationally recognized expert in genomics and cancer research, known for pioneering genome-wide sequence analysis in human cancers. Delfi's team comprises leading experts in cancer biology, bioinformatics, machine learning, and public health. The company's innovative approach has the potential to significantly impact early cancer detection, offering a more comprehensive and accessible screening method compared to existing technologies.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Blood Tests, Cancer Detection
Technology
AI, Machine Learning
Tags
Biotech, Healthtech
Model Types
Software, Data
Revenue Type(s)
Recurring
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
Global
When was Delfi Diagnostics founded?
Delfi Diagnostics was founded in 2019.
Where is Delfi Diagnostics's headquarters located?
Delfi Diagnostics's headquarters is located in Baltimore, MD, US.
When was Delfi Diagnostics's last funding round?
Delfi Diagnostics's most recent funding round was for $225M (USD) in July 2022.
How many employees does Delfi Diagnostics have?
Delfi Diagnostics has 235 employees as of Feb 5, 2024.
How much has Delfi Diagnostics raised to-date?
As of July 05, 2023, Delfi Diagnostics has raised a total of $330.5M (USD) since Jul 18, 2022.
Add Comparison
Total Raised to Date
$330.5M
USD
Last Update Jul 18, 2022
Last Deal Details
$225M
USD
Jul 18, 2022
Series B
Total Employees Over Time
235
As of Feb 2024
Delfi Diagnostics Address
301 W 29th St
Baltimore,
Maryland
21218
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts